bioactive

A collection of 19170 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification;

Well-chosen quantity: only contains 989 bioactive compounds after careful selection

A collection of 27752 bioactive compounds for high-throughput screening, high-content screening, cell induction and target identification.

A unique collection of 1080 bioactive lipids related compounds for high throughput screening (HTS) and high content screening (HCS), including Agonists & Antagonists, Endocannabinoids, Farnesyl/geranylgeranyl derivates, HETEs deHETEs, hepoxilins, Polyunsa

A unique collection of 1600 antibacterial bioactive compounds, a powerful tool for antibacterial drug development;

609 non-steroidal anti-inflammatory compounds for high-throughput and high-content screening.

A collection of 499 selected human endogenous metabolites for high throughput and high content screening.

A unique collection of 3163 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening;

A collection of 230 small-molecule compounds approved by the U.S. FDA for veterinary use, suitable for high-throughput screening (HTS) and high-content screening (HCS)

A unique collection of 1133 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents;

A unique collection of 3260 anti-infective compounds including anti-bacterial, anti-fungi, anti-Human Cytomegalovirus (HCMV), anti-HIV, anti-SARS, anti-influenza, etc;

A unique collection of 523 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening;

A unique collection of 280 bioactive compounds specifically targeting adrenergic receptors, effective tool for screening new drugs or new target identification;

A unique collection of 188 compounds targeting histaminergic receptor and melatonin receptor for high throughput screening (HTS) and high content screening (HCS) for new drugs;

600 well-chosen unique anti-parasitic small molecules;

A unique collection of 2684 fluorochemicals that can be used for high through-put screening (HTS) and high content screening (HCS);

A unique collection of 489 microbial natural products for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1147 monomers from 60 TCM plants, a powerful tool for anti-COVID-19 drug discovery, can be used for HTS and HCS screening;

A unique collection of 2450 anti-obesity compounds for high throughput and high content screening;

A unique collection of 490 osteogenesis related compounds for high throughput and high content screening;

A unique collection of 2240 reprogramming signaling pathway-related bioactive small molecule compounds for high-throughput, high-content screening.

A collection of 234 wine components, suitable for high-throughput and high-content screening.